...
首页> 外文期刊>Surgery today >Long-term outcomes of video-assisted thoracoscopic surgery lobectomy vs. thoracotomy lobectomy for stage IA non-small cell lung cancer
【24h】

Long-term outcomes of video-assisted thoracoscopic surgery lobectomy vs. thoracotomy lobectomy for stage IA non-small cell lung cancer

机译:视频辅助胸腔镜手术术术的长期结果与胸部肺切除术治疗IA非小细胞肺癌

获取原文
获取原文并翻译 | 示例
           

摘要

ObjectivesVideo-assisted thoracoscopic surgery (VATS) lobectomy is performed widely for patients with clinical stage I non-small cell lung cancer (NSCLC) because of its superior short-term outcomes to those of thoracotomy lobectomy. However, the long-term outcomes of VATS lobectomy vs. thoracotomy lobectomy remain controversial.MethodsWe reviewed the clinical data of 202 consecutive patients who underwent lobectomy for clinical stage IA NSCLC at our institution between January, 2008 and December, 2013. Stage IA NSCLC was confirmed pathologically in 162 of these patients, 60 of whom underwent VATS lobectomy and 102 of whom underwent thoracotomy lobectomy. We compared the perioperative clinical factors and outcomes of these two groups, using a propensity score-matched analysis.ResultsIn an analysis of 58 matched cases, the VATS group showed less blood loss, a shorter duration of chest tube placement, a shorter postoperative hospital stay, and a lower peak C-reactive protein value, despite a longer operative time. The VATS group also had significantly longer survival than the thoracotomy group [5-year overall survival, 100% vs. 87%, respectively (p=0.01); 5-year disease-free survival, 100% vs. 86% (p=0.03)].ConclusionsThese findings suggest that VATS may have better long-term as well as short-term outcomes than thoracotomy for patients with early-stage NSCLC.
机译:对象视频辅助胸镜手术(VATS)肺切除术是广泛的,用于临床阶段I非小细胞肺癌(NSCLC),因为其与胸廓切开术术术的卓越短期结果。然而,VATS肺切除术的长期结果仍然存在争议。近期审查了2008年1月至2013年1月至12月期间临床阶段IA NSCLC的202名连续患者的临床资料。阶段IA NSCLC是在这些患者的162名患者中诊断出来,其中60名患有大桶肺切除术和102人接受了胸廓切开术术。我们比较了这两组的围手术期临床因素和结果,使用倾向得分匹配的分析。评分分析58个匹配的病例,VATS组显示出较少的血液损失,胸部管置于较短的术后住院尽管有更长的操作时间,但尽管持续时间较长,但较低的C-反应蛋白值。 VATS组的存活率比胸廓术群体显着更长[5年整体生存率,分别为100%vs.87%(P = 0.01); 5年疾病生存,100%vs.86%(p = 0.03)]。结论结果表明,VATS可能具有比早期NSCLC患者的胸廓切开术的长期和短期成果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号